That therapy works by unmasking tumor cells, allowing T-cells to see and target them. The study showed that T-cells expressing the cell receptor CD38 were more susceptible to exhaustion.

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Currently available agents target CD38, uniformly expressed by myeloma cells. Engineering CAR T cells to target solid tumors ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple ... Sarclisa is a CD38-directed antibody ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Darzalex – also an anti-CD38 drug – was first approved in 2015 ... that Sanofi is hoping will continue a renaissance for its cancer business along with Libtayo (cemiplimab), a PD-1 inhibitor ...

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Kangpu Biopharma receives China NMPA’s IND approval for KPG-818 to treat relapsed/refractory multiple myeloma: Hefei, China Saturday, March 1, 2025, 14:00 Hrs [IST] Kangpu Bioph ...